Medigene announces participation at six upcoming investor and scientific conferences
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming investor and scientifi…
Newsrooms
Medigene and academic partners publish a method to identify T cell receptors against viral antigens
Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) announces that a scientific article on a method to identify T cell…
Medigene AG: Medigene presents automated platform for TCR identification at CAR-TCR Summit
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), will demonstrate the use of its automated high-throughput screening (HT…
Medigene AG: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
Medigene AG: Medigene reports results of first six months 2017
Growing revenues from core business immunotherapies, clinical trial application for second immunotherapy submitted, fina…
Medigene AG: Medigene berichtet Ergebnisse für das erste Halbjahr 2017
Die Medigene AG (FWB: MDG1, Prime Standard, TecDAX), ein Immunonkologie-Unternehmen mit klinischen Projekten fokussiert…
Medigene AG: Medigene and academic partners publish a method to enhance adoptive T-cell therapies
Article in "Cancer Research" published in collaboration with scientists from nine academic research groups in Berlin, Mu…
Medigene AG: Reports outcome of Annual General Meeting and announces new Supervisory Board Members
. - Shareholders approve all resolutions with a high majority - Dr. Keith Manchester, Ronald Scott and Dr. Gerd Zettlme…
Medigene AG: Medigene announces participation at six national and international conferences
Medigene AG (FWB: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming scientific and investo…
Medigene AG: Announces target and outlines design for its first clinical trial in TCR cancer immunotherapy
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), today announced details on the Company's first clinical trial with T-ce…